AZAmir Ziaee

Amir Ziaee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amir Ziaee has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical consequences of tocilizumab consumption time on COVID-19 patients

    by Shahin Keshtkar Rajabi, Amir Ziaee, Farshad Divsalar, Elnaz Hemmati, Mohammad Amin Abbasi

    Background & Aims: Studies have shown that treating COVID-19 with tocilizumab is associated with lower death risks and mechanical ventilation needs. However, the definite effectiveness of this drug based on the timing of its use is still controversial due to various findings. Some studies have shown that the timing of ...

  • Open Access

    Primary adrenal insufficiency and myocarditis in COVID-19 disease: a case report

    by Delaram Eskandari, Amir Ziaee, Abdollah Amirfarhangi Anbardan, Elahe Zeinali, Atefe Tirkan

    Background: COVID-19 has different manifestations from respiratory to GI problems, and some of them are more common, but some are rare. Reporting rare cases can significantly advance our understanding of the disease. Case presentation: In this case, we report an 18-year-old teenage boy with chest pain and resistant hypotension following COVID-19 infection, finally diagnosed as primary adrenal insufficiency and COVID-19 myocarditis. Conclusion: Adrenal insufficiency can be life-threatening due to its adverse effects on hemodynamic and electrolyte equilibrium. In addition, COVID-19 induced myocarditis can make the situation more complicated.


  • Open Access

    Efficacy of Dexamethasone and Methylprednisolone in Hospitalization Outcomes of COVID-19 Patients: A Comparative Retrospective Study

    by Mohammad Amin Abbasi, Amir Ziaee, Alireza Hejrati, Seyyed Alireza Hosseini, Lina Hejrati, Shahin Keshtkar Rajabi

    Background: Control of the COVID-19 pandemic, its treatment, and prevention of mortality and morbidity have been the main focus of researchers over the past two years. Due to disagreement on the usefulness of different corticosteroids in the treatment of COVID-19, this work compared the efficacy of dexamethasone and methylprednisolone in the treatment outcomes of intensive critical care (ICU) patients. Methods: The present retrospective cohort study examined clinical records of 105 COVID-19 patients hospitalized in the ICUs of Firoozabadi Hospital in 2021. Clinical outcomes, including the length of hospital stay, the need for a ventilator, and mortality, were compared between patients who received either dexamethasone (DXM) or methylprednisolone (MP). Data were analyzed by SPSS V.20 software at P < 0.05 as statistical significance. Results: The mean Âą SD ages of the patients in the DXM and MP groups were 58.82 Âą 19.29 and 60.66 Âą 14.17 years, respectively, without a statistically significant difference (P > 0.05). The mean duration of hospitalization was 8.14 Âą 4.36 days in the DXM group and 6.80 Âą 3.34 days in the MP group (P = 0.295). Also, 19 (33.3%) cases in the DXM group an, 19 (39.6%) in the MP group needed mechanical ventilation during hospitalization (P = 0.546). Finally, 30 (52.6%) patients in the DXM group and 27 (56.2%) in the MP group died. Conclusions: The findings indicated no significant difference in the mean duration of hospitalization, the need for a ventilator, and mortality in COVID-19 ICU patients treated with methylprednisolone or dexamethasone. There is a need to perform meta-analyses owing to conflicting results regarding the effects of different corticosteroids on the COVID-19 course.

  • Open Access

    Association of plasma total testosterone level and metabolic syndrome in adult males

    by Alireza Hejrati, Amir Ziaee, Mohammad Pourmahmudian, Elham Bayani, Mehrnaz Ghavamipour, Maryam Saatchi

    Introduction: Low testosterone level has strongly been correlated with body fat accumulation and abdominal obesity in men. Objectives: This study aimed to evaluate testosterone level in men with and without metabolic syndrome to determine the relationship between testosterone and metabolic syndrome. Patients and Methods: This case-control study was conducted on 172 cases of metabolic syndrome and 172 participants as a control group in Rasoul Akram hospital, Tehran, Iran. Demographic characteristics, fasting blood sugar (FBS), high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol, triglyceride (TG), and testosterone levels were recorded. SPSS version 21.0 and SAS version 9.1 were used for statistical analysis. Level of significance was considered 0.05. Results: The mean age of the two groups were 45.1Âą9.3 years and 41.5 Âą11.2 years, respectively. There was a significant difference in serum testosterone levels between both groups and low testosterone levels were associated with metabolic syndrome (PConclusion: According to the results, low level of testosterone was related to the presence of metabolic syndrome in adult males. Future studies can investigate diagnostic value of testosterone level in this syndrome.


  • Open Access

    Changes in the size of the thyroid in patients with benign non-toxic multinodular goiter after radioactive iodine therapy

    by Iraj Heydari, Maryam Honardoost, Sedighe Moradi, Fatemeh Golgiri, Hamidreza Dehnad, Saba Moradi, Amir Ziaee

    Background: Multinodular goiter (MNG) is regarded as one of the most common causes of hyperthyroidism, particularly in areas of mild-to-moderate iodine deficiency. The present study aims to explore the effects of the radioactive iodine (RAI) therapy on benign non-toxic MNG and evaluate its side effects. Methods: Patients with benign ...


  • Open Access

    Association of hematological indices with prediabetes: A cross-sectional study

    by Amir Ziaee, Azam Ghorbani, Saied Kalbasi, Alireza Hejrati, Saba Moradi

    Association of hematological indices with prediabetes: A cross-sectional study


  • Open Access

    Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus

    by Amir Ziaee, Neda Esmailzadehha, Maryam Honardoost

    Objective: All the aforementioned data have stimulated interest in studying other potential therapies for T1DM including noninsulin pharmacological therapies. The present study attempts to investigate the effect of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus.Method: In a single-center, placebo-controlled study (IRCT201102165844N1) we compared the results of two clinical trials conducted in two different time periods on 40 patients with Type-1 diabetes mellitus. In the first section, metformin was given to the subjects.After six months, metformin was replaced with acarbose in the therapeutic regimen. In both studies, subjects were checked for their BMI, FBS, HbA1C, TGs, Cholesterol, LDL, HDL, 2hpp, unit of NPH and regular insulin variations.Results: Placebo-controlled evaluation of selected factors has showna significant decrease in FBS and TG levels in the metformin group during follow up but acarbose group has shown substantial influence on two hour post prandial (2hpp) and regular insulin intake decline.Moreover, Comparison differences after intervention between two test groups has shown that metformin has had superior impact on FBS and HbA1C decline in patients. Nonetheless, acarbose treatment had noteworthy influence on 2hpp, TGs, Cholesterol, LDL, and regular insulin intake control.Conclusion: The results of this experiment demonstrate that the addition of acarbose or metformin to patients with Type-1 diabetes mellitus who are controlled with insulin is commonly well tolerated and help to improve metabolic control in patients.


  • Awareness of osteoporosis among female head of household: an Iranian experience

    by Pouria Khashayar, Mostafa Qorbani, Abbasali Keshtkar, Patricia Khashayar, Amir Ziaee, Bagher Larijani

    More than 81% of the studied women had a poor knowledge of different aspects of osteoporosis and its complications, suggesting that more educational programs targeting women in particular are needed to help improve the osteoporosis practice in the societies and reduce the burden of the disease.


  • Association of meat and dairy consumption with normal weight metabolic obesity in men: the Qazvin Metabolic Diseases Study

    by Sima Hashemipour, Neda Esmailzadehha, Mahdieh Mohammadzadeh, Amir Ziaee

    Insulin resistance (IR) is not limited to obese individuals. Normal weight individuals may also be insulin resistant. The aim of this study was to determine the association of lifestyle and diet patterns with IR in normal weight Iranian men. This cross-sectional study was conducted in 232 men with a body mass index lower than 25 kg/m2 (aged 20–72 years old) between September 2010 and April 2011 in Qazvin, Iran. Metabolically obese normal weight (MONW) was defined as IR using the homeostatic model assessment (HOMA). The optimal cut point to diagnose IR was the 80th percentile of HOMA-IR values in normal subjects. The HOMA-IR cut point was 2.48. Dietary pattern was assessed by a semi-quantitative food frequency questionnaire. Data were analyzed using backward logistic regression and ANCOVA. Fat and meat consumption and energy intake in subjects with MONW were more than subjects without MONW. Each serving of meat consumption was associated with three times increased risk of MONW (OR: 3.06), while each serving of dairy consumption was associated with 56 % lower risk of MONW with borderline significance (OR: 0.64). Adjusted mean of HOMA-IR in the first tertile of dairy consumption was significantly higher than other tertiles. Adjusted HOMA-IR value in the third tertile of meat consumption was significantly higher than the second tertile. Higher meat consumption was associated with MONW in men. Higher meat consumption and lower dairy consumption were associated with higher means of HOMA-IR.